Finance

Lists
Why is TDOC up 6.75%?
Dive Deeper
TDOC:NYSE
Teladoc Health Inc
$9.49
+6.75%
(+0.60) 1D
Nov 4, 11:54:44 AM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TDOC...
Open
$8.89
High
$9.52
Low
$8.83
Mkt. cap
1.73B
Avg. vol.
4.60M
Volume
2.99M
52-wk high
$9.89
52-wk low
$4.40
EPS
-$0.86
Beta
2.00
Shares outstanding
182.29M
No. of employees
5K
Open
$8.89
High
$9.52
Low
$8.83
Mkt. cap
1.73B
Avg. vol.
4.60M
Volume
2.99M
52-wk high
$9.89
52-wk low
$4.40
EPS
-$0.86
Beta
2.00
Shares outstanding
182.29M
No. of employees
5K
News stories
From web sources and news partners
Profile
Teladoc Health, Inc. is an American telemedicine and virtual healthcare company founded in 2002. Headquartered in New York City, its services include telehealth, employer-sponsored health plans, 24/7 care, mental health, diabetes and hypertension management, primary care, prescriptions, medical opinions, AI and analytics, telehealth devices and licensable platform services. The company uses telephone and videoconferencing software and mobile apps to provide on-demand remote medical care. Teladoc Health is active in over 175 countries, and is traded on the New York Stock Exchange. It is the first and largest telemedicine company in the United States, and has acquired numerous other companies including BetterHelp in 2015, Best Doctors in 2017, and Catapult Health in 2025. Wikipedia
About Teladoc Health Inc
CEO-
Employees5.12K
Founded2002
Headquarters-
SectorHealth care
Industry-
Analyst ratings
Based on 14 analysts giving stock ratings to TDOC in the past 3 months
Hold
Buy
4
Hold
9
Sell
1
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for TDOC in the last 3 months.
Highest
Current $9.49
$10.50 (+10.64%)
Average
$9.05 (-4.64%)
Lowest
$6.50 (-31.51%)
Analyst
Recommendation
Action
Price target
Projected
Date
Peter Warendorf
Barclays
Hold
Maintained
$9.00
-5.2%
11/04/2026
Unknown Analyst
Leerink Partners
Hold
Maintained
$8.50
-10.4%
11/02/2026
David Toung
Argus Research
Sell
Downgraded
-
-
11/02/2026
Michael Wiederhorn
Oppenheimer
Buy
Maintained
$10.00
+5.4%
11/02/2026
Kevin Caliendo
UBS
Hold
Reiterated
$9.00
-5.2%
11/02/2026
Lisa Gill
J.P. Morgan
Hold
Reiterated
$10.00
+5.4%
10/30/2026
Richard Close
Canaccord Genuity
Buy
Maintained
$10.00
+5.4%
10/28/2026
Ryan MacDonald
Needham
Hold
Reiterated
-
-
10/29/2026
Sarah James
Cantor Fitzgerald
Buy
Reiterated
$10.00
+5.4%
10/28/2026
Sean Dodge
BMO Capital
Hold
Maintained
$7.00
-26.2%
10/28/2026
David Larsen
BTIG
Hold
Maintained
-
-
10/28/2026
David Grossman
Stifel Nicolaus
Hold
Reiterated
$6.50
-31.5%
10/29/2026
Allen Lutz
Bank of America Securities
Buy
Reiterated
$10.50
+10.6%
10/28/2026
Jailendra Singh
Truist Financial
Hold
Maintained
-
-
09/01/2026
Charles Rhyee
TD Cowen
Hold
Maintained
$6.00
-36.8%
08/03/2026
Daniel Grosslight
Citi
Hold
Maintained
$7.50
-21%
08/03/2026
Stan Berenshteyn
Wells Fargo
Hold
Maintained
$6.00
-36.8%
07/30/2026
Brian Tanquilut
Jefferies
Hold
Maintained
$8.00
-15.7%
07/30/2026
Elizabeth Anderson CFA
Evercore ISI
Hold
Maintained
$7.50
-21%
07/30/2026
Ryan Daniels
William Blair
Hold
Reiterated
-
-
07/29/2026
David Roman
Goldman Sachs
Buy
Maintained
$8.00
-15.7%
05/27/2026
George Hill
Deutsche Bank
Buy
Upgraded
$11.00
+15.9%
03/10/2026
Scott Schoenhaus
KeyBanc
Hold
Maintained
-
-
02/27/2026
Steven Valiquette
Mizuho Securities
Hold
Maintained
$6.00
-36.8%
02/26/2026
Jessica Tassan
Piper Sandler
Buy
Reiterated
$9.00
-5.2%
02/26/2026
Last report
Oct 28, 2026
Fiscal period
Q3 2026
-$0.12 / -$0.19
+36.47%beat
Revenue / Est. (USD)
605.10M / 590.71M
+2.44%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
642.27M
613.84M
606.93M
605.10M
Cost of goods sold
197.05M
197.53M
190.84M
190.26M
Cost of revenue
197.05M
197.53M
190.84M
190.26M
Research and development expenses
71.61M
67.86M
62.86M
65.55M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
305.74M
304.90M
296.82M
280.96M
Operating expense
472.19M
465.05M
450.59M
436.97M
Total operating expenses
669.24M
662.57M
641.42M
627.23M
Operating income
-26.97M
-48.73M
-34.50M
-22.13M
Other non operating income
378.00K
-196.00K
-2.19M
-285.00K
EBT including unusual items
-33.62M
-60.84M
-37.91M
-26.28M
EBT excluding unusual items
-24.59M
-47.80M
-35.32M
-20.31M
Income tax expense
-8.48M
3.00M
997.00K
655.00K
Effective tax rate
25.21%
-4.92%
-2.63%
-2.49%
Other operating expenses
-
-
-
-
Net income
-25.14M
-63.84M
-38.91M
-26.93M
Net profit margin
-3.91%
-10.40%
-6.41%
-4.45%
Earnings per share
-0.10
-0.28
-0.20
-0.12
Interest and investment income
6.95M
6.49M
6.48M
7.04M
Interest expense
-4.95M
-5.37M
-5.11M
-4.94M
Net interest expenses
2.00M
1.12M
1.37M
2.10M
Depreciation and amortization charges
2.80M
2.46M
2.47M
2.19M
EBITDA
28.67M
5.48M
19.73M
31.66M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps